Here we are again approaching the holiday season and rounding out another amazing year. So much has happened at Omixon this year and we are very proud to say our company and our role as experts in fostering the adoption of NGS for HLA has grown so much with the help of our amazing customers and partners among the HLA community and the broader genomics research community as well.
In 2015 Omixon Field Application Scientists trained over 50 labs in Holotype HLA across more than 20 countries in North America, Europe, the Middle East and Asia-Pacific. Many of those labs contributed data towards our Early Access Program, which is now the largest study of NGS for HLA, covering more than 26,000 allele calls with an average accuracy of 99.97%. We will be submitting this for peer-reviewed publication in 2016 and make additional announcements about it closer to the time.
We are continuing to develop innovative products and in 2016 we will launch new software, add more loci, complete CE IVD certification and introduce a range of new configurations for our flagship Holotype HLA product. Many of these are just around the corner, so stay tuned for Early Access details and other programs.
One of the real joys of the holiday season is having the opportunity to say thank you. We do want to take this moment to thank you all for your business and support for the year. Your continued partnership has greatly contributed to our success in increasing the growth and global competitiveness of our businesses.
From all of us at Omixon, we wish you a safe, enjoyable holiday and much success in the New Year. With our own words: Happy Ho, Ho, Ho… Holotyping and see you next year! 🙂
